Accuracy of Down syndrome risks produced in a first-trimester screening programme incorporating fetal nuchal translucency thickness and maternal serum biochemistry

2002 ◽  
Vol 22 (3) ◽  
pp. 244-246 ◽  
Author(s):  
Kevin Spencer
Keyword(s):  
Down Syndrome ◽  
Screening Programme ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Serum Biochemistry ◽  
Maternal Serum ◽  
First Trimester Screening ◽  
Trimester Screening

scholarly journals Impact of Ductus Venosus Assessment in Screening Down Syndrome Protocols: An Improved Strategy in a Fetal Medicine Unit

2009 ◽  
Vol 3 (2) ◽  
pp. 10-17 ◽  
Author(s):  
Mónica Echevarria ◽  
Carmen Comas ◽  
M Angeles Rodríguez ◽  
Joan Nicolau ◽  
Bernat Serra ◽  
...  
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Serum Biochemistry ◽  
Screening Strategy ◽  
Maternal Serum ◽  
Ductus Venosus ◽  
Early Evaluation ◽  
Invasive Test ◽  
Screening Efficiency

ABSTRACT Objective To estimate the improvement in screening efficiency when ductus venosus (DV) Doppler studies are added to existing Down syndrome (DS) screening protocols. Methods First-trimester combined screening for trisomy 21 was prospectively carried out, from October 2003 to March 2008, in 8842 consecutive singleton pregnancies attended in our tertiary reference center. The nuchal translucency (NT) and the pulsatility index for veins for DV were calculated. The maternal serum biochemistry was measured using the Kryptor analyzer, at the same time of the scan (one step strategy) or before it (two step strategy). The detection rate (DR) and false-positive rates for standard screening strategy (maternal age, NT and biochemistry) and the same strategy but including DV assessment were calculated. Results Successful DV assessment was possible in the 95.3% of cases, representing a total of 8426 cases. Down syndrome was identified in 34 pregnancies (prevalence of DS 1:250). For a fixed screen positive rate of 5%, the addition of the DV assessment improves the DR from 85 to 94% and, for a fixed DR of 85%, it reduces the number of unnecessary invasive tests from 3.7 to 3.2%. Conclusion Early evaluation of DV can be introduced to standard DS screening strategies in experienced centers as a first level test to reduce invasive test rate derived from the existing protocols.

Maternal serum placental growth factor and α -fetoprotein testing in first trimester screening for Down syndrome

2013 ◽  
Vol 33 (5) ◽  
pp. 457-461 ◽  
Author(s):  
Kim Donalson ◽  
Steve Turner ◽  
Lesley Morrison ◽  
Päivi Liitti ◽  
Christel Nilsson ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Growth Factor ◽  
First Trimester ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
First Trimester Screening ◽  
Trimester Screening

First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers

2005 ◽  
Vol 25 (10) ◽  
pp. 901-905 ◽  
Author(s):  
Antoni Borrell ◽  
Anna Gonce ◽  
Josep M. Martinez ◽  
Virginia Borobio ◽  
Albert Fortuny ◽  
...  
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Serum Markers ◽  
Ductus Venosus ◽  
Doppler Studies ◽  
First Trimester Screening ◽  
Trimester Screening

Extended First-Trimester Screening Using Multiple Sonographic Markers and Maternal Serum Biochemistry: A Five-Year Prospective Study

2014 ◽  
Vol 35 (4) ◽  
pp. 296-301 ◽  
Author(s):  
Ching-Hua Hsiao ◽  
Po-Jen Cheng ◽  
S.W. Steven Shaw ◽  
Jenn-Jeih Hsu ◽  
Ran-Chou Chen ◽  
...  
Keyword(s):  
Prospective Study ◽  
First Trimester ◽  
Serum Biochemistry ◽  
Maternal Serum ◽  
First Trimester Screening ◽  
Trimester Screening

scholarly journals Fetal Down syndrome screening models for developing countries; Part I: Performance of Maternal Serum Screening

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Chanane Wanapirak ◽  
Wirawit Piyamongkol ◽  
Supatra Sirichotiyakul ◽  
Fuanglada Tongprasert ◽  
Kasemsri Srisupundit ◽  
...  
Keyword(s):  
Developing Countries ◽  
Down Syndrome ◽  
Reference Range ◽  
First Trimester ◽  
Maternal Serum ◽  
Second Trimester ◽  
First Trimester Screening ◽  
Maternal Serum Screening ◽  
Serum Screening ◽  
Trimester Screening

Abstract Background To identify the performance of fetal Down syndrome (DS) screening for developing countries. Methods A prospective study on MSS (maternal serum screening) with complete follow-ups (n = 41,924) was conducted in 32 network hospitals in the northern part of Thailand. Various models of MSS were tested for performance. Results MSS based on Caucasian reference range resulted in very high false positive rate (FPR; 13%) in our country, compared to the rate of 7.8% with our own (Thai) reference range, whereas the detection rate was comparable. As individual screening, C-S (contingent first trimester screening including PAPP-A, and free beta-hCG, classified as a) high risk [> 1:30], indicated for invasive diagnosis; b) intermediate risk [1:30–1500], indicated for STS; and c) low risk [< 1:1500], need no further tests.) was the most effective model (sensitivity 84.9%, FPR 7.7%) but nearly one-third needed the second trimester test (STS) because of intermediate results. Additionally, about one-third had their first visits in the second trimester and had no chance of FTS (first trimester screening). C-S plus STS had a sensitivity of 82.4% and FPR 8.1% whereas independent first and second trimester screening model (I-S) gave the sensitivity of 78.4% and FPR of 7.5% but was much more convenient and practical. Conclusion C-S plus STS was the most effective models while I-S model was also effective and may be better for developing countries because of its simplicity and feasibility.

Sign in / Sign up

Export Citation Format

Share Document